ARS Pharmaceuticals, Inc. logo

ARS Pharmaceuticals, Inc. (SPRY) Q1 2026 Earnings

SPRY·Reported May 15, 2026·Before market open

ARS Pharmaceuticals, Inc. reported Q1 2026 revenue of $22.7M (+184.5% YoY), beat analyst consensus of $22.2M by $481.0K. Diluted EPS came in at $-0.61 (-74.3% YoY), missed the $-0.53 consensus by $0.08.

Revenue
$22.7Mbeat by $481.0K
Consensus: $22.2M
Diluted EPS
$-0.61missed by $0.08
Consensus: $-0.53
SEC

SEC Filings

Earnings release8-K · 0001193125-26-220671
Quarterly report10-Q · 0001193125-26-225142

Financial Snapshot

Trailing eight quarters through Q1 2026

View all metrics

Q1 2026 Earnings FAQ

Common questions about ARS Pharmaceuticals, Inc.'s Q1 2026 earnings report.

ARS Pharmaceuticals, Inc. (SPRY) reported Q1 2026 earnings on May 15, 2026 before market open.

ARS Pharmaceuticals, Inc. reported revenue of $22.7M and diluted EPS of $-0.61 for Q1 2026.

Revenue beat the consensus estimate of $22.2M by $481.0K. EPS missed the consensus estimate of $-0.53 by $0.08.

Compared to the same quarter a year prior, revenue grew 184.5% from $8.0M a year earlier and diluted EPS declined 74.3% from $-0.35.

You can read the 8-K earnings release (0001193125-26-220671) and the 10-Q periodic report (0001193125-26-225142) directly on SEC EDGAR. The filing index links above go to sec.gov.